Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13454638 | 0.85 | POLG (0.46) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL10903439 | 0.82 | POLG (0.45) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL585724 | 0.82 | POLG (0.51) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL18394211 | 0.82 | P2RY2 (0.51) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL24309037 | 0.81 | POLG (0.51) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL26102705 | 0.81 | POLG (0.51) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL872890 | 0.80 | PDE3A (0.47) | POLBPOLA1 | |
| SCHEMBL6141746 | 0.79 | POLG (0.51) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL17215886 | 0.79 | POLG (0.51) | POLBPOLGP2RY6P2RY2P2RY4 | |
| SCHEMBL25396644 | 0.79 | POLG (0.51) | POLBPOLGP2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008113072-A2 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | claimed |
| EP-3268021-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | Oxeia Biopharmaceuticals, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144978-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2008113072-A2 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | disclosed |